These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 12176872)

  • 1. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome.
    Saunthararajah Y; Nakamura R; Nam JM; Robyn J; Loberiza F; Maciejewski JP; Simonis T; Molldrem J; Young NS; Barrett AJ
    Blood; 2002 Sep; 100(5):1570-4. PubMed ID: 12176872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Changes of HLA-DR15 and immunoglobulin, T lymphocyte subsets in patients with aplastic anemia, myelodysplastic syndrome and their significance].
    Cui JX; Pei MF; Zhang GS; Xu M
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):111-5. PubMed ID: 20137129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndrome.
    Maciejewski JP; Follmann D; Nakamura R; Saunthararajah Y; Rivera CE; Simonis T; Brown KE; Barrett JA; Young NS
    Blood; 2001 Dec; 98(13):3513-9. PubMed ID: 11739151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome.
    Steensma DP; Dispenzieri A; Moore SB; Schroeder G; Tefferi A
    Blood; 2003 Mar; 101(6):2156-8. PubMed ID: 12411290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of human leukocyte antigen class II alleles with response to immunosuppressive therapy in Korean aplastic anemia patients.
    Song EY; Kang HJ; Shin HY; Ahn HS; Kim I; Yoon SS; Park S; Kim BK; Park MH
    Hum Immunol; 2010 Jan; 71(1):88-92. PubMed ID: 19819281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome.
    Saunthararajah Y; Nakamura R; Wesley R; Wang QJ; Barrett AJ
    Blood; 2003 Oct; 102(8):3025-7. PubMed ID: 12829603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome.
    Kadia TM; Borthakur G; Garcia-Manero G; Faderl S; Jabbour E; Estrov Z; York S; Huang X; Pierce S; Brandt M; Koller C; Kantarjian HM; Ravandi F
    Br J Haematol; 2012 May; 157(3):312-20. PubMed ID: 22360602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An increased HLA DR2 frequency is seen in aplastic anemia patients.
    Nimer SD; Ireland P; Meshkinpour A; Frane M
    Blood; 1994 Aug; 84(3):923-7. PubMed ID: 8043874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roles of DRB1 *1501 and DRB1 *1502 in the pathogenesis of aplastic anemia.
    Sugimori C; Yamazaki H; Feng X; Mochizuki K; Kondo Y; Takami A; Chuhjo T; Kimura A; Teramura M; Mizoguchi H; Omine M; Nakao S
    Exp Hematol; 2007 Jan; 35(1):13-20. PubMed ID: 17198869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor necrosis factor polymorphism affects transplantation outcome in patients with myelodysplastic syndrome but not in those with chronic myelogenous leukemia, independent of the presence of HLA-DR15.
    Newell LF; Gooley T; Hansen JA; Stirewalt DL; Petersdorf EW; Deeg HJ
    Biol Blood Marrow Transplant; 2010 Dec; 16(12):1700-6. PubMed ID: 20541027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High frequency of human leukocyte antigen class II DRB1*1602 haplotype in Greek patients with myelodysplastic syndrome and of DRB1*1501 in the low-risk subgroup.
    Kritikou-Griva E; Spyropoulou-Vlachou M; Tsagarakis NJ; Goumakou E; Vrani V; Galanopoulos A; Papadhimitriou SI; Androutsos G; Paterakis G; Stavropoulos-Giokas C
    Hum Immunol; 2012 Mar; 73(3):278-81. PubMed ID: 22244918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SF3B1 Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic Syndromes.
    Zhang Q; Haider M; Al Ali NH; Lancet JE; Epling-Burnette PK; List AF; Padron E; Komrokji RS
    Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):400-406.e2. PubMed ID: 32179032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HLA DR2: a predictive marker in response to cyclosporine therapy in aplastic anemia.
    Ihan O; Beksaç M; Arslan O; Ozcan M; Koç H; Akan H; Gürman G; Konuk N; Uysal A
    Int J Hematol; 1997 Oct; 66(3):291-5. PubMed ID: 9401274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia.
    Kojima S; Hibi S; Kosaka Y; Yamamoto M; Tsuchida M; Mugishima H; Sugita K; Yabe H; Ohara A; Tsukimoto I
    Blood; 2000 Sep; 96(6):2049-54. PubMed ID: 10979946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental and clinical characteristics in myelodysplastic syndrome patients with or without HLA-DR15 allele.
    Xiao L; Qiong L; Yan Z; Zheng Z; Luxi S; Li X; Ying T; Yizhi L; Quan P
    Hematol Oncol; 2010 Jun; 28(2):98-103. PubMed ID: 19593744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunophenotype of myeloid granulocytes: a pilot study for distinguishing myelodysplastic syndrome and aplastic anemia by flow cytometry.
    Huang M; Li J; Zhao G; Sui X; Zhao X; Xu H
    Int J Lab Hematol; 2010 Jun; 32(3):275-81. PubMed ID: 19968721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased expression of HLA DR2 in acquired aplastic anemia and its impact on response to immunosuppressive therapy.
    Usman M; Adil SN; Moatter T; Bilwani F; Arian S; Khurshid M
    J Pak Med Assoc; 2004 May; 54(5):251-4. PubMed ID: 15270183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Changes and clinical significance of CD8(+) T cell subset in patients with aplastic anemia, myelodysplastic syndrome and acute myeloid leukemia].
    Zhang JY; Xu HZ; Yin DM; Feng XM; Sui XH; Cui B; Ma CY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):203-8. PubMed ID: 23484720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome.
    Garg R; Faderl S; Garcia-Manero G; Cortes J; Koller C; Huang X; York S; Pierce S; Brandt M; Beran M; Borthakur G; Kantarjian H; Ravandi F
    Leukemia; 2009 Jul; 23(7):1297-302. PubMed ID: 19242494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human leukocyte antigen (HLA) DR15 is associated with reduced incidence of acute GVHD in HLA-matched allogeneic transplantation but does not impact chronic GVHD incidence.
    Battiwalla M; Hahn T; Radovic M; Roy H; Wahab A; Duman E; Bajwa R; Padmanabhan S; Becker J; Barrett AJ; McCarthy PL
    Blood; 2006 Mar; 107(5):1970-3. PubMed ID: 16282347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.